Intravenous iron for heart failure with evidence of iron deficiency: a meta-analysis of randomised trials

Fraser J. Graham1 · Pierpaolo Pellicori1 · Ian Ford1 · Mark C. Petrie2 · Paul R. Kalra3 · John G. F. Cleland1

Received: 27 January 2021 / Accepted: 3 March 2021 / Published online: 23 March 2021 © The Author(s) 2021

Abstract

Background The recent AFFIRM-AHF trial assessing the effect of intravenous (IV) iron on outcomes in patients hospitalised with worsening heart failure who had iron deficiency (ID) narrowly missed its primary efficacy endpoint of recurrent hospitalisations for heart failure (HHF) or cardiovascular (CV) death. We conducted a meta-analysis to determine whether these results were consistent with previous trials.

Methods We searched for randomised trials of patients with heart failure investigating the effect of IV iron vs placebo/control groups that reported HHF and CV mortality from 1st January 2000 to 5th December 2020. Seven trials were identified and included in this analysis. A fixed effect model was applied to assess the effects of IV iron on the composite of first HHF or CV mortality and individual components of these.

Results Altogether, 2,166 patients were included (n = 1168 assigned to IV iron; n = 998 assigned to control). IV iron reduced the composite of HHF or CV mortality substantially [OR 0.73; (95% confidence interval 0.59–0.90); p = 0.003]. Outcomes were consistent for the pooled trials prior to AFFIRM-AHF. Whereas first HHF were reduced substantially [OR 0.67; (0.54–0.85); p = 0.0007], the effect on CV mortality was uncertain but appeared smaller [OR 0.89; (0.66–1.21); p = 0.47].

Conclusion Administration of IV iron to patients with heart failure and ID reduces the risk of the composite outcome of first heart failure hospitalisation or cardiovascular mortality, but this outcome may be driven predominantly by an effect on HHF. At least three more substantial trials of intravenous iron are underway.

Graphic abstract

In a meta-analysis of 7 trials, administration of IV iron to patients with heart failure and iron deficiency reduces the risk of the composite outcome of first heart failure hospitalisation or cardiovascular mortality, but this outcome is driven predominantly by an effect on heart failure hospitalisations.

Extended author information available on the last page of the article
Introduction

Patients with heart failure often have evidence of iron deficiency (ID), with or without anaemia, which is associated with more severe symptoms, lower exercise capacity and higher rates of hospitalisations for heart failure (HHF) and mortality [1, 2]. In an individual patient meta-analysis of four trials including 839 patients with heart failure with reduced ejection fraction (HFrEF) and serum markers of ID, Anker and colleagues suggested that administration of intravenous iron (IV) reduced the risk of first and recurrent HHF when compared to placebo [3]. Recently, the AFFIRM-AHF trial narrowly missed its primary efficacy endpoint of recurrent HHF or cardiovascular (CV) death [4]. Therefore, we produced an updated the meta-analysis to investigate whether the effects of IV iron were consistent amongst the randomised trials reported so far and whether sufficient evidence had accumulated to indicate a conclusive effect on HHF and CV mortality.

Methods

We searched for English language trials from 1st January 2000 to 5th December 2020 in PubMed using pre-specified search terms (see Supplements), and from additional sources including a recent systematic review [5]. Only published randomised trials investigating the effects of IV iron compared to a control group that did not receive IV iron in patients with heart failure, regardless of participants’ left ventricular ejection fraction, the formulation of IV iron, concomitant therapy, or definition of ID, that reported either HHF or CV mortality were included in the main report. If mortality was not explicitly reported but HHF was, it was assumed that no deaths had occurred. An additional analysis was done including two unpublished trials, with data derived from the meta-analysis reported by Anker et al. [3].

Data were extracted by two independent reviewers (FG and PP). Deaths not clearly declared as CV or non-CV were adjudicated independently by two authors, both of whom are experienced in clinical end-point adjudication. Adjudication was based on the clinical information provided by authors in the text. Disparities were resolved by discussion or by checking with a third author (JGFC). Outcomes assessed were the composite of HHF or CV mortality as first events, and HHF as a first event and CV mortality separately. Data analysed were the numbers of first events and numbers of participants in each treatment arm for each trial. Odds ratios and 95% confidence intervals for the effect of treatment with IV iron relative to control were calculated for each trial. The data were analysed using both fixed effects (primary analysis) and random effects models. Forest plots with odds ratios and corresponding (95% confidence intervals) were produced and reported. A level of significance of 5% was considered statistically significant.

To assess the impact of results from the largest trial to date, additional analysis comparing odds ratios for studies excluding AFFIRM-AHF to the AFFIRM-AHF trial alone were carried out.

All analyses were conducted with Review Manager (RevMan) Version 5.4 (The Cochrane Collaboration, 2020).

Results

We identified 19 reports assessing the effect of iron therapy in patients with heart failure (Fig. 1). After excluding 12 reports [6–17], mainly because they were not randomised-controlled trials or did not report relevant outcomes (Supplementary Table S1), seven trials (Table 1) that enrolled 2,166 patients (n = 1168 assigned to IV iron; n = 998 assigned to the control/placebo) were included in the primary analysis [4, 18–23]. The most common definition of ID was a ferritin < 100 µg/L and/or, if ferritin was 100–300 µg/L, a TSAT of < 20%. Most trials excluded patients with a very low haemoglobin (less than 8–10 g/dL) or with values greater than 15 g/dL. [4, 19]. Only two trials followed patients for > 6 months [4, 19]. Five trials used ferric carboxymaltose and two used iron sucrose [21, 22].

In the primary analysis, IV iron reduced the composite outcome of HHF or CV death: OR 0.73 [0.59–0.90]; p = 0.003 (Fig. 2a). HHF occurred in 175 (15%) patients given IV iron and 227 (23%) assigned to control: OR 0.67 [0.54–0.85]; p = 0.0007 (Fig. 2b). CV deaths occurred in 93 (8%) patients administered IV iron and in 98 (10%) assigned to control: OR 0.89 [0.66–1.21]; p = 0.47 (Fig. 2c). Adding data from the two unpublished trials to the main analysis did not substantially alter these results (Supplementary Figure S1).

When AFFIRM-AHF was excluded from the model, the point estimates for the effect of IV iron were OR 0.59 [0.39–0.89]; p = 0.01 for the composite outcome, OR 0.57 [0.36–0.80]; p = 0.02 for HHF and OR 0.66 [0.34–1.28]; p = 0.22 for CV mortality (Table 2 and Fig. 3). The odds ratios for all outcomes were not significantly different for the pooled data excluding AFFIRM-AHF compared to AFFIRM-AHF alone (Table 3).

In random effects models, IV iron reduced the composite outcome [OR 0.74 (0.60–0.91); p = 0.005] but neither HHF
[OR 0.64 (0.40–1.04); \( p = 0.07 \)] nor CV mortality [OR 0.91 (0.67–1.24); \( p = 0.56 \)] (Supplementary Figure S2). Results were similar when AFFIRM-AHF was excluded (Table 2 and Supplementary Figure S3).

### Discussion

This meta-analysis suggests that IV iron reduces the risk of the composite outcome of first HHF or CV death for patients with serum markers of ID and heart failure. This result was driven predominantly by an effect on HHF with no convincing evidence of a reduction in CV mortality. Because HHF is associated with a higher risk of CV mortality, the effect of IV iron for each outcome might be expected to be rather similar. The relatively small number of deaths, the short duration of follow-up and the play of chance might explain this possible anomaly. A longer duration of follow-up might show a greater effect on CV mortality, but the trial with the longest follow-up to date, albeit only one year, showed little effect on this outcome [4]. The AFFIRM-AHF trial suggests that the reduction in hospitalisations for heart failure is not observed until 8–12 weeks after administration of IV iron, consistent with its benefits being mediated through the synthesis of new red blood cells, myoglobin and other metalloproteins. Accordingly, large effects observed in some small trials lasting 3 months or less may reflect chance effects.

The effects of IV iron appeared somewhat greater in a pooled analysis of trials excluding AFFIRM-AHF, although differences were not statistically significant. IV iron might be more effective in clinically stable populations. Differences in study design, inclusion criteria, iron dosing and length of follow-up may affect the outcome. The small size of some trials confounded statistical assessment of heterogeneity. Instead, we produced both fixed and random effects models which, for the composite outcome, yielded similar results, although less secure for effects on HHF in the random effects model.

Whether the definition of ID used in these trials is optimal is uncertain. Using a TSAT < 20% alone might be a better guide to ID than one based on ferritin [24–26]. This is important because giving IV iron to patients who are not iron-deplete is unlikely to be beneficial. Fortunately, ID appears common in patients with heart failure and therefore an effect might be detected even if the diagnostic accuracy of the test for ID is poor. Perhaps most patients with heart failure have ID and the key question is how severe it is, rather than whether it is present; ID should not be a binary, all-or-nothing classification.
Table 1 Characteristics of included trials

|                                | Toblli et al | FERRIC-HF | FAIR-HF | CONFIRM-HF | EFFECT-HF | PRACTICE-ASIA-HF | AFFIRM-AHF |
|--------------------------------|-------------|-----------|---------|------------|-----------|------------------|-----------|
| **Year of publication**        | 2007        | 2008      | 2009    | 2014       | 2017      | 2018             | 2020      |
| **Country**                    | Argentina   | UK and Poland | Europe and Argentina | Europe | Europe and Australia | Singapore | 15 countries (International) |
| **Number of patients (IV iron: control)** | 40 (1:1) | 35 (2:1) | 459 (2:1) | 301 (1:1) | 174 (1:1) | 49 (1:1) | 1108 (1:1) |
| **Double-blind**               | Yes         | No        | Yes     | Yes        | No        | No               | Yes       |
| **Definition of ID**           | $F < 100$ or $T \leq 20\%$ | $F < 100$ or $T < 20\% + F 100-300$ | $F < 100$ or $T < 20\% + F 100-299$ | $F < 100$ or $T < 20\% + F 100-300$ | $F < 100$ or $T < 20\% + F 100-300$ | $F < 100$ or $T < 20\% + F 100-299$ |
| **Main inclusion criteria (Hb: g/dL)** | • LVEF $\leq 35\%$ | • LVEF $\leq 45\%$ | • LVEF $\leq 45\%$ | • LVEF $\leq 45\%$ | • LVEF $\leq 45\%$ | • LVEF $\leq 45\%$ | • LVEF $\leq 45\%$ |
|                               | • NYHA II-IV | • NYHA II-III | • NYHA II-III | • NYHA II/III | • NYHA II or III | • NYHA II or III | • NYHA II or III |
|                               | • Anaemia    | • Anaemia | • Anaemia | • Anaemia | • Anaemia | • Anaemia | • Anaemia |
| **Age (years)**                | 75          | 63        | 68      | 70         | 64        | 63               | 71        |
| **Women (%)**                  | –           | 29        | 54      | 47         | 25        | 22               | 45        |
| **Ischaemic aetiology (%)**    | 63          | 74        | 80      | 83         | –         | –                | 47        |
| **LVEF (%)**                   | 31 $\pm$ 4  | 30 $\pm$ 7 | 32 $\pm$ 6 | 37 $\pm$ 8 | 33 $\pm$ 9 | 39 $\pm$ 18     | 33 (10)   |
| **NT-proBNP (pg/ml)**          | 256 $\pm$ 125 | –        | –       | 2511 $\pm$ 5006 | 1576* | –               | 4743 (2781–8128)* |
| **eGFR (ml/min/1.73 m$^2$)**   | –           | –         | 64      | 66         | 52        | –                | –         |
| **Haemoglobin (g/dL)**         | 10.3 $\pm$ 0.6 | 12.6 $\pm$ 1.2 | 11.9 $\pm$ 1.3 | 12.3 $\pm$ 1.4 | 12.9 $\pm$ 1.3 | 11.6 $\pm$ 1.9 | 12.3 $\pm$ 1.6 |
| **Ferritin (µg/L)**            | 73 $\pm$ 30 | 62 $\pm$ 37 | 53 $\pm$ 55 | 57 $\pm$ 48 | 48* | 91 $\pm$ 80 | 84±62 |
| **TSAT (%)**                   | 20 $\pm$ 1  | 20 $\pm$ 8 | 18 $\pm$ 13 | 20 $\pm$ 18 | 17* | 16 $\pm$ 10 | 15±8 |
| **Form of iron therapy (mean dose)** | Iron sucrose; 1000 mg | Iron sucrose; 1433 mg | FCM; n/a | FCM; 1500 mg | FCM; 1204 mg | FCM; 1000 mg | FCM; 1352 mg |
| **Follow-up**                  | 24 weeks    | 18 weeks  | 24 weeks | 52 weeks   | 24 weeks  | 12 weeks         | 52 weeks  |
| **Outcomes reported**          | HHF         | +         | +       | +          | +         | +                | +         |
| **CVM**                        | –           | +         | +       | +          | +         | +                | +         |

Data shown are for the active group only, but this is also representative of the control group. Data presented as mean±SD or count (%) unless otherwise stated. If data not available/reported, cell filled (–). *Median and (Q1–Q3) reported.

*Not specifically reported but derived from reported outcomes in the paper and from the individual-patient-data meta-analysis by Anker et al.—see reference [3].

**ID** iron deficiency, **F** ferritin (µg/L), **T** transferrin saturation (%), **LVEF** left ventricular ejection fraction, **NYHA** New York Heart Association, **Hb** haemoglobin, **NT-proBNP** N-terminal pro-brain natriuretic peptide, **IV** intravenous, **eGFR** estimated glomerular filtration rate, **FCM** ferric carboxymaltose, **HHF** hospitalisation for heart failure, **CVM** cardiovascular mortality.
Fig. 2  Fixed-effects meta-analysis model of all included trials detailing the pooled effect of intravenous iron on the composite of first hospitalisations for heart failure or cardiovascular mortality (a), and first hospitalisation for heart failure (b) and cardiovascular mortality (c) alone. IV intravenous, CI confidence interval.

| Study or Subgroup | IV iron | Controls | Events Patients | Events Patients | Odds Ratio M-H, Fixed, 95% CI Year | Odds Ratio M-H, Fixed, 95% CI Year |
|-------------------|---------|----------|----------------|----------------|-----------------------------------|-----------------------------------|
|                   |         |          |                |                | 2007                             | 2007                              |
| Toblli 2007       | 20      | 20       | 5              | 5              | 0.07 [0.00, 1.34]                 | 0.07 [0.00, 1.34]                 |
| Okonko 2008       | 24      | 24       | 1              | 1              | 0.91 [0.07, 11.23]                | 0.91 [0.07, 11.23]                |
| Anekar 2009       | 304     | 304      | 10             | 10             | 0.49 [0.20, 1.21]                 | 0.49 [0.20, 1.21]                 |
| Ponikowski 2014   | 150     | 150      | 32             | 32             | 0.51 [0.27, 0.95]                 | 0.51 [0.27, 0.95]                 |
| van Veldhuisen 2017 | 88   | 88       | 10             | 10             | 1.09 [0.44, 2.71]                 | 1.09 [0.44, 2.71]                 |
| Yeo 2018          | 24      | 24       | 5              | 5              | 1.05 [0.26, 4.22]                 | 1.05 [0.26, 4.22]                 |
| Ponikowski 2020   | 181     | 181      | 555            | 555            | 0.78 [0.61, 1.00]                 | 0.78 [0.61, 1.00]                 |
| Total (95% CI)    | 1168    | 998      | 100%           | 100%           | 0.73 [0.59, 0.96]                 | 0.73 [0.59, 0.96]                 |
| Total events      | 227     | 272      |                |                |                                  |                                  |

Heterogeneity: Chi² = 5.80, df = 5 (P = 0.46), I² = 0%

Test for overall effect: Z = 2.60 (P = 0.003)

Table 2  Summary of results from meta-analysis models, with and without AFFIRM-AHF, and AFFIRM-AHF alone, assessing the effect of IV iron on outcomes.

| Outcome          | IV iron | Controls | Fixed effect | Random effect |
|------------------|---------|----------|--------------|---------------|
|                  | Events  | Patients | OR (95% CI)  | p             | OR (95% CI)  | p             |
| AFFIRM-AHF excluded |         |          |              |               |               |               |
| CVM or HHF       | 46      | 610      | 0.59 (0.39, 0.89) | 0.01 | 0.62 (0.41, 0.93) | 0.02 |
| HHF              | 33      | 610      | 0.57 (0.36, 0.90) | 0.02 | 0.60 (0.28, 1.28) | 0.19 |
| CVM              | 16      | 610      | 0.66 (0.34, 1.28) | 0.22 | 0.72 (0.36, 1.43) | 0.35 |
| AFFIRM-AHF       |         |          |              |               |               |               |
| CVM or HHF       | 181     | 558      | 0.78 (0.61, 1.00) | –  | 0.78 (0.61, 1.00) | –   |
| HHF              | 142     | 558      | 0.71 (0.55, 0.93) | –  | 0.71 (0.55, 0.93) | –   |
| CVM              | 77      | 558      | 0.97 (0.69, 1.36) | –  | 0.97 (0.69, 1.36) | –   |
| All Trials       |         |          |              |               |               |               |
| CVM or HHF       | 227     | 1168     | 0.73 (0.59, 0.90) | 0.003 | 0.74 (0.60-0.91) | 0.005 |
| HHF              | 175     | 1168     | 0.67 (0.54, 0.85) | 0.0007 | 0.64 (0.40, 1.04) | 0.07 |
| CVM              | 93      | 1168     | 0.89 (0.66, 1.21) | 0.47 | 0.91 (0.67, 1.24) | 0.56 |

IV intravenous, OR odds ratio, CI confidence interval, CVM cardiovascular mortality, HHF hospitalisation for heart failure.
We did not conduct subgroup analyses, which are best left to an individual-patient-data (IPD) meta-analysis that can adjust for confounding variables. In an IPD meta-analysis [3], lower TSAT but not lower serum ferritin predicted greater benefit from IV iron. In AFFIRM-AHF it appeared that lower serum ferritin or a lower TSAT were associated with greater benefit from IV iron, but >80% of participants had a TSAT < 20%. Further analyses are required. Haemoglobin concentration has not predicted benefit but, because women have lower concentrations than men, such analyses may be confounded by participants' sex. The AFFIRM-AHF trial enrolled patients with new-onset heart failure, 

Table 3  Comparison of fixed-effects odds ratios (ORs) between pooled trials prior to AFFIRM-AHF and AFFIRM-AHF

|                          | Composite endpoint | Hospitalisation for heart failure | Cardiovascular mortality |
|--------------------------|--------------------|-----------------------------------|--------------------------|
| **Odds ratio (95% confidence interval)** | 0.59 (0.39, 0.89) | 0.57 (0.36, 0.90) | 0.66 (0.34, 1.28) |
| **P for comparison**     | 0.26               | 0.41                             | 0.31                     |
| **OR (95% confidence interval) of comparison** | 0.76 (0.47, 1.22) | 0.80 (0.47, 1.36) | 0.68 (0.32, 1.43) |
which is unusual for trials of heart failure; these patients may have had somewhat less benefit from IV iron possibly because they were less likely to have true ID or because the determinants of outcome in such patients are different. In AFFIRM-AHF patients with ischaemic cardiomyopathy appeared to have greater benefit; the reasons for this are unclear. The reduction in events with IV iron, compared to control, might have been underestimated because treatments for heart failure might have been more likely to be intensified in the control group who did not receive the symptomatic benefits of iron therapy. This possibility should be explored in the future analysis of substantial long-term trials.

Results from three other large ongoing trials should clarify the effects of IV iron on morbidity and mortality in patients with HFrEF and ID and provide further insights into the possible predictors of response [27]. Trials in heart failure with preserved ejection fraction are also underway but limited data currently exist [23].

Limitations

We did not investigate the effect of IV iron on all-cause mortality as this is not yet reported for AFFIRM-AHF. The composite outcome reported for CONFIRM-HF [19] was HHF and all-cause mortality, which included one non-CV death amongst patients assigned to iron and two to placebo. This would not materially alter our overall results. An analysis of recurrent HHF rather than just the first event would make the result more robust but requires access to IPD. An IPD meta-analysis has many advantages when exploring the interaction amongst variables [28–30]. In particular, an IPD would have allowed analysis of the potential interaction between sex and the effects of IV iron. However, aggregate data have the advantage that it includes all the published data rather than the proportion where IPD is available to the authors. Each type of meta-analysis has advantages, and they are complimentary. All meta-analyses should be interpreted cautiously, particularly for analyses involving a number of small studies where there will be little power to detect heterogeneity. Fixed effects meta-analysis provides an estimate of an average treatment effect in the studies conducted but uncertainty about heterogeneity may make it difficult to extrapolate that effect to a particular clinical context. Random effects analyses assume that studies have underlying treatment effects arising from a random distribution and provide estimates of the average of, and variation in, the treatment effect in that distribution. However, if the variation is systematic and not random then the random effects analysis may not be helpful in extrapolating a treatment effect to a new situation. In the context of this analysis, length of follow-up, clinical status of patients at recruitment and IV iron dosing strategy are systematically different amongst the studies. Whether these factors systematically impact the treatment effect is difficult to determine with the data available.

Conclusion

In a meta-analysis of seven trials, administration of IV iron to patients with heart failure and ID reduced the risk of the composite outcome of heart failure hospitalisation or cardiovascular mortality in the following 12 months. To date, this outcome is driven predominantly by an effect on HHF. Longer term effects of repeated administration of IV iron are unknown. More evidence is desirable.

Supplementary Information The online version contains supplementary material available at https://doi.org/10.1007/s00392-021-01837-8.

Data availability Not applicable.

Code availability Not applicable.

Declarations

Conflict of interest FG reports receipt of sponsorship from Vifor to attend an international meeting. JGFC reports receipt of personal honoraria for lectures and advisory boards from Pharmacosmos and Vifor, and from AstraZeneca, Amgen, Bayer, Novartis and Servier. IF reports receipt of research grants from Vifor and Pharmacosmos. MCP reports receipt of research grants from Vifor and Pharmacosmos. MCP and JGFC are supported by the British Heart Foundation (BHF) Centre of Research Excellence Award (RE/13/5/30177 and RE/18/6/34221+). PRK reports receipt of personal honoraria for lectures, advisory boards and research/quality improvement grants from Pharmacosmos and Vifor. PRK reports receipt of personal honoraria for lectures and advisory boards from Akebia, Amgen, AstraZeneca, Bayer and Servier.

Ethics approval Not applicable.

Informed consent Not applicable.

Consent for publication All authors consent to the publication of this manuscript in its current form.
References

1. Klip IT, Comin-Colet J, Voors AA, Ponikowski P, Enjuanes C, Banasiak W, Lok DJ, Rosentery P, Torrens A, Polonski L, van Veldhuisen DJ, van der Meer P, Jankowska EA (2013) Iron deficiency in chronic heart failure: an international pooled analysis. Am Heart J 165(4):575–582

2. Jankowska EA, Rozentery P, Witkowska A, Nowak J, Hartmann O, Ponikowski B, Borudolin- Nadzieja L, Banasiak W, Polonski L, Filippatos MJJV, Anker SD, Ponikowski P (2010) Iron deficiency: an ominous sign in patients with systolic chronic heart failure. Eur Heart J 31(15):1872–1880

3. Anker SD, Kirwan BA, van Veldhuisen DJ, Filippatos G, Comin-Colet J, Rutschitzka F, Lüscher TF, Arutyunov GP, Motro M, Mori C, Roubert B, Pocock SJ, Ponikowski P (2018) Effects of ferric carboxymaltose on hospitalisations and mortality rates in iron-deficient heart failure patients: an individual patient data meta-analysis. Eur J Heart Fail 20(1):125–133

4. Ponikowski P, Kirwan B-A, Anker SD, McDonagh T, Dorobantu M, Drozdz J, Fabien V, Filippatos G, Göhring UM, Keren A, Klintibidez I, Kraegten H, Martinez FA, Metra M, Milicic D, Nicolau JC, Olhsson M, Parkhomkeno A, Pascual-Fidal GA, Rutschitzka F, Sim D, Skouri H, van der Meer P, Lewis BS, Comin-Colet J, von Haehling S, Cohen-Solal A, Danchin N, Doehner W, Dargie HJ, Morto M, Butler J, Friede T, Jensen KH, Pocock S, Janowska EA (2020) Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial. Lancet 396(10266):1895–1904

5. Anand IS, Gupta P (2018) Anaemia and iron deficiency in heart failure. Circulation 138(1):80–98

6. Silverberg DS, Wexler D, Blum M, Tchebiner JZ, Sheps D, Keren G, Schwartz D, Baruch R, Yachni T, Steinbruch S, Shapira I, Iaina A (2003) The effect of correction of anaemia in diabetics and non-diabetics with severe resistant congestive heart failure and chronic renal failure by subcutaneous erythropoietin and intravenous iron. Nephrol Dial Transplant 18(1):141–146

7. Silverberg DS, Wexler D, Blum M, Schwartz D, Keren G, Iaina SA, (2003) Effect of correction of anaemia with erythropoietin and intravenous iron in resistant heart failure in octogenarians. Isr Med Assoc J 5(5):337–339

8. Charles-Edwards G, Amoral N, Sleight A, Ayis S, Catibog N, McDonagh T, Monaghan M, Amin-Youssef G, Kemp GI, Shah AM, Okonko DO (2019) Effect of iron isomaltoside on skeletal muscle energetics in patients with chronic heart failure and iron deficiency: FERRIC-HF II randomized mechanistic trial. Circulation 139(21):2386–2398

9. Núñez J, Miñana G, Cardells I, Palau P, Coll Cardiol 48(6):1225–1227

10. Usmanow RI, Zueva EB, Silverberg DS, Shaked M (2008) Intravenous iron without erythropoietin for the treatment of iron deficiency anaemia in patients with moderate to severe congestive heart failure and chronic kidney insufficiency. J Nephrol 21(2):236–242

11. Reed BN, Blair EA, Thudium EM, Waters SB, Suetca CA, Jensen BC, Rodgers JE (2015) Effects of an accelerated intravenous iron regimen in hospitalized patients with advanced heart failure and iron deficiency. Pharmacother J Hum Pharmacol Drug Ther 35(1):64–71

12. Mirdamadi A, Arefeh A, Garakaryaghi M, Pourmoghadad A (2018) Beneficial effects of the treatment of iron deficiency on clinical condition, left ventricular function, and quality of life in patients with chronic heart failure. Acta Biomed 89(2):214–219

13. Silverberg DS, Wexler D, Sheps D, Blum M, Keren G, Baruch R, Schwartz D, Yachni T, Steinbruch S, Sharipia I, Laniado S, Iaina A (2001) The effect of correction of mild anaemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study. J Am Coll Cardiol 37(7):1775–1780

14. Lewis GD, Malhotra R, Hernandez AF, McNulty SE, Smith A, Michael Felker G, Tang WHW, LaRue SJ, Redfield MM, Semigran MJ, Givertz MM, van Buren P, Whellan D, Anstrom KJ, Shah MR, Desvigne-Nickens P, Butler J, Braunwald E (2017) Effect of oral iron repletion on exercise capacity in patients with heart failure with reduced ejection fraction and iron deficiency the IRON OUT HF randomized clinical trial. JAMA 317(19):1958–1966

15. Beck-De-Silva L, Piardi D, Soder S, Rohde LE, Pereira-Barretto AC, De Albuquerque D, Bocchi E, Vilas-Boas F, Moura LZ, Monter MWA, Rassi S, Clausell NL (2013) IRON-HF study: a randomised trial to assess the effects of iron in heart failure patients with anaemia. Int J Cardiol 168(4):3439–3442

16. Toblli JE, Di Gennaro F, Rivas C (2015) Changes in echocardiographic parameters in iron deficiency patients with heart failure and chronic kidney disease treated with intravenous iron. Hear Lung Circ 24(7):686–695

17. Anker SD, Colet JC, Filippatos G, Willenheimer R, Dickstein K, Drexei H, Lüscher TF, Bart B, Banasiak W, Niegowska J, Kirwan B, Mori C, von Eisenhart RB, Pocock SJ, Poole-Wilson PA, Ponikowski P (2009) FAIR-HF trial investigators. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med 361(25):2436–2448

18. Ponikowski P, Van Veldhuisen DJ, Comin-Colet J, Ertl G, Komajda M, Mareev V, McDonagh T, Parkhomkeno A, Taazzi L, Lev-Besque V, Mori C, Roubert B, Filippatos G, Rutschitzka F, Anker SD (2015) CONFIRM-HF Investigators. Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency. Eur Heart J 36(11):657–668

19. van Veldhuisen DJ, Ponikowski P, Van Der Meer P, Metra M, Böhm M, Doletsky A, Voors AA, Macdougall IC, Anker SD (2013) IRON-HF study: a randomized placebo-controlled study to assess the effects of intravenous iron sucrose on exercise tolerance in anemic and iron-deficient heart failure patients: an individual patient data meta-analysis. Eur J Heart Fail 15(1):1374–1383

20. Toblli JE, Lombrana A, Duarte P, Di Gennaro F (2007) Intravenous iron reduces NT-pro brain natriuretic peptide in anemic patients with chronic heart failure and renal insufficiency. J Am Coll Cardiol 50(17):1657–1665

21. Okonko DO, Grzeslo A, Witkowska T, Mandel AKJ, Slater RM, Roughton M, Foldes G, Thum T, Majda J, Banasiak W, Missouris CG, Poole-Wilson PA, Anker SD, Ponikowski P (2008) Effect of intravenous iron sucrose on exercise tolerance in anemic and iron-deficient heart failure patients: a pilot randomized placebo-controlled study. Circulation 136(15):1374–1383

22. van Veldhuisen DJ, Filippatos MJ, Anker SD, Colet JC, Filippatos G, Willenheimer R, Dickstein K, Drexei H, Lüscher TF, Bart B, Banasiak W, Niegowska J, Kirwan B, Mori C, von Eisenhart RB, Pocock SJ, Poole-Wilson PA, Ponikowski P (2009) FAIR-HF trial investigators. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med 361(25):2436–2448

23. Toblli JE, Lombrana A, Duarte P, Di Gennaro F (2007) Intravenous iron reduces NT-pro brain natriuretic peptide in anemic patients with chronic heart failure and renal insufficiency. J Am Coll Cardiol 50(17):1657–1665

24. Beverborg NG, Klip IjT, Meijers WC, Voors AA, Vegter EL, Van Der Wal HJ, Swinkels DW, van Pelt J, Mulder AB, Bulstra SK,
Vellenga E, Mariani MA, de Boer RA, van Veldhuisen DJ, van der Meer P (2018) Definition of iron deficiency based on the gold standard of bone marrow iron staining in heart failure patients. Circ Heart Fail 11(2):e004519

25. Cleland JGF, Zhang J, Pellicori P, Dicken B, Dierckx R, Shoaib A, Wong K, Rigby A, Goode K, Clark AL (2016) Prevalence and outcomes of anemia and hematocrit deficiencies in patients with chronic heart failure. JAMA Cardiol 1(5):539–547

26. Moliner P, Jankowska EA, van Veldhuisen DJ, Farre N, Rozentryt P, Enjuanes C, Polonski L, Moroño O, Voors AA, Ponikowski P, van der Meer P, Comin-Colet J (2017) Clinical correlates and prognostic impact of impaired iron storage versus impaired iron transport in an international cohort of 1821 patients with chronic heart failure. Int J Cardiol 243:360–366

27. Pellicori P, Khan MJI, Graham FJ, Cleland JGF (2020) New perspectives and future directions in the treatment of heart failure. Heart Fail Rev 25(1):147–159

28. Cleland JG, Abraham WT, Linde C, Gold MR, Young JB, Claude Daubert J, Sherfesee L, Wells GA, Tang ASL (2013) An individual patient meta-analysis of five randomized trials assessing the effects of cardiac resynchronization therapy on morbidity and mortality in patients with symptomatic heart failure. Eur Heart J 34(46):3547–3556

29. Cleland JGF, Bunting KV, Flather MD, Altman DG, Holmes J, Coats AJS, Manzino L, McMurray JVF, Rutschitzka F, van Veldhuisen DJ, von Lueder TG, Böhmer M, Andersson B, Kjekshus J, Packer M, Rigby AS, Rosano G, Wedel H, Hjalmarson A, Wijkstra J, Koetcha D (2018) Beta-blockers in Heart Failure Collaborative Group. Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials. Eur Heart J 39(1):26–35

30. Linde C, Cleland JGF, Gold MR, Claude Daubert J, Tang ASL, Young JB, Sherfesee L, Abraham WT (2018) The interaction of sex, height, and QRS duration on the effects of cardiac resynchronization therapy on morbidity and mortality: an individual-patient data meta-analysis. Eur J Heart Fail 20(4):780–791

Authors and Affiliations

Fraser J. Graham1 · Pierpaolo Pellicori1 · Ian Ford1 · Mark C. Petrie2 · Paul R. Kalra3 · John G. F. Cleland1

Fraser J. Graham
fraser.graham@glasgow.ac.uk

1 Robertson Centre for Biostatistics, University of Glasgow, Boyd Orr Building, University Avenue, Glasgow, UK

2 British Heart Foundation Cardiovascular Research Centre, University of Glasgow, Glasgow, UK

3 Department of Cardiology, Portsmouth Hospitals University NHS Trust, Portsmouth, UK